Exhibit 99.2

Fresenius Medical Care AG & Co. KGaA

COMPLETE OVERVIEW OF THE SECOND QUARTER AND

FIRST HALF YEAR 2020

July 30, 2020

Investor Relations

phone: +49 6172 609 2525

email: ir@fmc-ag.com

Content:
Statement of earnings	page 2
Segment information	page 3
Balance sheet	page 4
Cash flow	page 5
Revenue development	page 6
Key metrics	page 7
Quality data	page 8
Reconciliation	page 9
Reconciliation adjusted results	page 10
Outlook 2020	page 11

Disclaimer

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Copyright by Fresenius Medical Care AG & Co. KGaA

July 30, 2020

1

Statement of earnings

	Three months ended June 30										Six months ended June 30
in € million, except share data, unaudited	2020			2019			Change		Change  at cc		2020			2019			Change		Change  at cc
Health Care Services	3,614			3,455			4.6	%	4.0	%	7,209			6,773			6.4	%	5.2	%
Health Care Products	943			890			6.0	%	7.5	%	1,836			1,705			7.7	%	8.3	%
Total revenue	4,557			4,345			4.9	%	4.7	%	9,045			8,478			6.7	%	5.8	%
Costs of revenue	3,121			3,014			3.6	%	3.7	%	6,198			5,881			5.4	%	4.8	%
Gross profit	1,436			1,331			7.9	%	7.0	%	2,847			2,597			9.7	%	8.2	%
Selling, general and administrative	738			795			-7.2	%	-7.4	%	1,593			1,516			5.1	%	4.2	%
(Gain) loss related to divestitures of Care Coordination activities	(5		)	(11		)	-59.7	%	-59.8	%	(29		)	(11		)	153.7	%	147.9	%
Research and development	51			48			4.4	%	3.4	%	96			77			25.3	%	23.8	%
Income from equity method investees	(4		)	(22		)	-82.6	%	-82.7	%	(24		)	(43		)	-42.8	%	-42.9	%
Operating income	656			521			25.8	%	24.0	%	1,211			1,058			14.5	%	12.4	%
Operating income margin in %	14.4		%	12.0		%					13.4		%	12.5		%
Interest income	(11		)	2			n.a.		n.a.		(20		)	(26		)	-23.0	%	-22.0	%
Interest expense	103			112			-8.2	%	-8.2	%	216			248			-12.9	%	-13.5	%
Interest expense, net	92			114			-19.6	%	-19.7	%	196			222			-11.7	%	-12.5	%
Income before taxes	564			407			38.6	%	36.2	%	1,015			836			21.5	%	19.0	%
Income tax expense	137			92			48.6	%	46.1	%	237			193			23.0	%	20.5	%
Net income	427			315			35.7	%	33.3	%	778			643			21.0	%	18.5	%
Net income attributable to noncontrolling interests	76			61			24.8	%	22.2	%	144			118			21.8	%	18.8	%
Net income attributable to shareholders of FMC-AG & Co. KGaA	351			254			38.3	%	36.0	%	634			525			20.8	%	18.5	%
Operating income	656			521			25.8	%	24.0	%	1,211			1,058			14.5	%	12.4	%
Depreciation, amortization and impairment loss	410			387			6.0	%	5.3	%	811			749			8.2	%	6.9	%
EBITDA	1,066			908			17.4	%	16.0	%	2,022			1,807			11.9	%	10.1	%
EBITDA margin in %	23.4		%	20.9		%					22.4		%	21.3		%
Weighted average number of shares	292,733,283			303,456,178							295,287,813			305,048,922
Basic earnings per share	€	1.20		€	0.84		43.4	%	41.0	%	€	2.15		€	1.72		24.8	%	22.4	%
Basic earnings per ADS	€	0.60		€	0.42		43.4	%	41.0	%	€	1.07		€	0.86		24.8	%	22.4	%

Statement of earnings

2

Segment information

	Three months ended June 30								Six months ended June 30
unaudited	2020		2019		Change		Change at cc		2020		2019		Change		Change at cc
Total
Revenue in € million	4,557		4,345		4.9	%	4.7	%	9,045		8,478		6.7	%	5.8	%
Operating income in € million	656		521		25.8	%	24.0	%	1,211		1,058		14.5	%	12.4	%
Operating income margin in %	14.4	%	12.0	%					13.4	%	12.5	%
Delivered Operating Income in € million	580		460		26.0	%	24.2	%	1,067		940		13.6	%	11.6	%
Days sales outstanding (DSO)									53		77
Employees (full-time equivalents)									124,736		119,631
North America
Revenue in € million	3,240		3,061		5.8	%	3.7	%	6,426		5,948		8.0	%	5.4	%
Operating income in € million	609		429		42.1	%	39.3	%	1,073		801		33.9	%	30.9	%
Operating income margin in %	18.8	%	14.0	%					16.7	%	13.5	%
Delivered Operating Income in € million	535		372		44.1	%	41.3	%	934		690		35.2	%	32.2	%
Days sales outstanding (DSO)									30		63
EMEA
Revenue in € million	687		648		6.0	%	8.0	%	1,366		1,301		5.0	%	6.1	%
Operating income in € million	78		96		-19.5	%	-18.6	%	179		235		-23.7	%	-23.3	%
Operating income margin in %	11.3	%	14.9	%					13.1	%	18.0	%
Delivered Operating Income in € million	77		94		-19.1	%	-18.3	%	177		232		-23.4	%	-23.1	%
Days sales outstanding (DSO)									92		101
Asia-Pacific
Revenue in € million	450		458		-1.7	%	-1.8	%	893		886		0.9	%	0.3	%
Operating income in € million	63		69		-8.7	%	-9.5	%	140		164		-14.6	%	-15.3	%
Operating income margin in %	14.1	%	15.1	%					15.7	%	18.5	%
Delivered Operating Income in € million	62		67		-7.4	%	-8.1	%	137		160		-14.1	%	-14.7	%
Days sales outstanding (DSO)									113		122
Latin America
Revenue in € million	170		172		-1.6	%	23.9	%	338		334		1.1	%	24.2	%
Operating income in € million	11		6		85.5	%	110.0	%	18		17		2.9	%	11.4	%
Operating income margin in %	6.4	%	3.4	%					5.3	%	5.2	%
Delivered Operating Income in € million	11		6		83.7	%	107.5	%	18		17		3.4	%	11.8	%
Days sales outstanding (DSO)									139		116
Corporate
Revenue in € million	10		6		98.8	%	96.2	%	22		9		137.3	%	133.6	%
Operating income in € million	(105	)	(79	)	32.9	%	32.5	%	(199	)	(159	)	24.8	%	24.3	%
Delivered Operating Income in € million	(105	)	(79	)	33.0	%	32.6	%	(199	)	(159	)	24.9	%	24.4	%

Segment information

3

Balance sheet

	June 30		December 31
in € million, except for net leverage ratio, unaudited	2020		2019
Assets
Current assets	8,182		7,165
Goodwill and intangible assets	15,508		15,444
Right of use assets	4,428		4,325
Other non-current assets	6,072		6,001
Total assets	34,190		32,935
Liabilities and equity
Current liabilities	8,064		7,059
Non-current liabilities	12,803		12,649
Total equity	13,323		13,227
Total liabilities and equity	34,190		32,935
Equity/assets ratio	39	%	40	%
Debt and lease liabilities
Short-term debt	876		1,150
Short-term debt from related parties	3		22
Current portion of long-term debt	1,513		1,447
Current portion of long-term lease liabilities	622		622
Current portion of long-term lease liabilities from related parties	21		17
Long-term debt, less current portion	6,274		6,458
Long-term lease liabilities, less current portion	4,039		3,960
Long-term lease liabilities from related parties, less current portion	130		106
Total debt and lease liabilities	13,478		13,782
Minus: Cash and cash equivalents (1)	(1,889	)	(1,008	)
Total net debt and lease liabilities	11,589		12,774
Reconciliation of annualized adjusted EBITDA and net leverage ratio to the most directly comparable IFRS financial measures
Net income	1,574		1,439
Income tax expense	446		402
Interest income	(56	)	(62	)
Interest expense	459		491
Depreciation and amortization	1,608		1,553
Adjustments (2)	97		110
Annualized adjusted EBITDA	4,128		3,933
Net leverage ratio	2.8		3.2

(1) The increase in cash and cash equivalents as of June 30, 2020 was primarily related to federal relief funding and advanced payments under the CARES Act and other COVID-19 relief.

Balance sheet

4

Cash flow statement

	Three months ended June 30				Six months ended June 30
in € million, unaudited	2020		2019		2020		2019
Operating activities
Net income	427		315		778		643
Depreciation / amortization / impairment loss	410		387		811		749
Change in working capital and other non-cash items	1,482		150		1,314		(464	)
Net cash provided by (used in) operating activities	2,319		852		2,903		928
In percent of revenue	50.9	%	19.6	%	32.1	%	10.9	%
Investing activities
Purchases of property, plant and equipment	(218	)	(296	)	(500	)	(497	)
Proceeds from sale of property, plant and equipment	2		3		4		4
Capital expenditures, net	(216	)	(293	)	(496	)	(493	)
Free cash flow	2,103		559		2,407		435
In percent of revenue	46.1	%	12.9	%	26.6	%	5.1	%
Acquisitions and investments, net of cash acquired, and purchases of intangible assets	(69	)	(94	)	(108	)	(1,923	)
Proceeds from divestitures	5		11		11		23
Acquisitions and investments, net of divestitures	(64	)	(83	)	(97	)	(1,900	)
Free cash flow after investing activities	2,039		476		2,310		(1,465	)

Cash flow

5

Revenue development

									Same
									market
					Change		Organic		treatment
in € million, unaudited	2020	2019	Change		at cc		growth		growth(1)
Three months ended June 30
Total revenue	4,557	4,345	4.9	%	4.7	%	4.4	%
Health Care Services	3,614	3,455	4.6	%	4.0	%	3.8	%	2.4	%
Thereof Dialysis Care revenue	3,224	3,120	3.3	%	2.8	%	2.2	%	2.4	%
Thereof Care Coordination revenue	390	335	16.4	%	14.4	%	19.9	%
Health Care Products	943	890	6.0	%	7.5	%	6.9	%
North America	3,240	3,061	5.8	%	3.7	%	3.7	%
Health Care Services	2,951	2,789	5.8	%	3.7	%	3.7	%	1.8	%(2)
Thereof Dialysis Care revenue	2,602	2,511	3.6	%	1.6	%	0.8	%	1.8	%(2)
Thereof Care Coordination revenue	349	278	25.5	%	23.0	%	31.8	%
Health Care Products	289	272	6.2	%	4.0	%	4.3	%
EMEA	687	648	6.0	%	8.0	%	6.9	%
Health Care Services	341	335	1.7	%	4.5	%	4.2	%	3.3	%
Health Care Products	346	313	10.6	%	11.8	%	9.9	%
Thereof Dialysis Products	324	296	9.5	%	10.8	%	8.7	%
Thereof Non-Dialysis Products	22	17	28.8	%	29.2	%	29.2	%
Asia-Pacific	450	458	-1.7	%	-1.8	%	-0.7	%
Health Care Services	196	210	-6.8	%	-8.8	%	-6.5	%	1.2	%
Thereof Dialysis Care revenue	155	153	1.1	%	-1.9	%	4.0	%	1.2	%
Thereof Care Coordination revenue	41	57	-28.0	%	-27.4	%	-33.4	%
Health Care Products	254	248	2.6	%	4.1	%	4.0	%
Thereof Dialysis Products	254	248	2.5	%	3.9	%	3.8	%
Thereof Non-Dialysis Products	0	—	n.a.		n.a.		n.a.
Latin America	170	172	-1.6	%	23.9	%	17.6	%
Health Care Services	119	121	-1.1	%	25.9	%	17.8	%	3.6	%
Health Care Products	51	51	-3.0	%	19.2	%	17.3	%
Corporate	10	6	98.8	%	96.2	%
Health Care Services	7	—	n.a.		n.a.
Health Care Products	3	6	-23.9	%	-24.2	%
Six months ended June 30
Total revenue	9,045	8,478	6.7	%	5.8	%	4.2	%
Health Care Services	7,209	6,773	6.4	%	5.2	%	3.9	%	2.8	%
Thereof Dialysis Care revenue	6,422	6,078	5.7	%	4.6	%	2.9	%	2.8	%
Thereof Care Coordination revenue	787	695	13.2	%	10.8	%	13.5	%
Health Care Products	1,836	1,705	7.7	%	8.3	%	5.3	%
North America	6,426	5,948	8.0	%	5.4	%	3.6	%
Health Care Services	5,859	5,469	7.1	%	4.5	%	3.3	%	2.4	%(2)
Thereof Dialysis Care revenue	5,173	4,883	5.9	%	3.3	%	1.5	%	2.4	%(2)
Thereof Care Coordination revenue	686	586	17.0	%	14.1	%	19.0	%
Health Care Products	567	479	18.4	%	15.5	%	7.9	%
EMEA	1,366	1,301	5.0	%	6.1	%	5.0	%
Health Care Services	682	659	3.5	%	5.0	%	4.3	%	2.8	%
Health Care Products	684	642	6.6	%	7.1	%	5.7	%
Thereof Dialysis Products	638	606	5.3	%	5.8	%	4.3	%
Thereof Non-Dialysis Products	46	36	28.8	%	29.0	%	29.0	%
Asia-Pacific	893	886	0.9	%	0.3	%	0.4	%
Health Care Services	414	409	1.2	%	-0.8	%	-0.5	%	2.9	%
Thereof Dialysis Care revenue	313	300	4.4	%	1.3	%	4.8	%	2.9	%
Thereof Care Coordination revenue	101	109	-7.5	%	-6.8	%	-14.1	%
Health Care Products	479	477	0.5	%	1.3	%	1.2	%
Thereof Dialysis Products	474	477	-0.5	%	0.3	%	0.1	%
Thereof Non-Dialysis Products	5	—	n.a.		n.a.		n.a.
Latin America	338	334	1.1	%	24.2	%	17.3	%
Health Care Services	240	236	1.9	%	27.2	%	18.7	%	4.2	%
Health Care Products	98	98	-0.7	%	16.9	%	14.1	%
Corporate	22	9	137.3	%	133.6	%
Health Care Services	14	—	n.a.		n.a.
Health Care Products	8	9	-6.1	%	-6.3	%

(1)same market treatment  growth = organic growth less price effects

(2)U.S. (excl. Mexico), same market treatment growth North America: 2.1% for the three months and 2.6% for the six months ended June 30, 2020.

Revenue development

6

Key metrics North America segment

	Three months ended June 30								Six months ended June 30
unaudited	2020		2019		Change		Change at cc		2020		2019		Change		Change at cc
Dialysis
Revenue in € million	2,891		2,783		3.9	%	1.8	%	5,740		5,362		7.1	%	4.4	%
Operating income in € million	567		428		32.5	%	30.0	%	984		760		29.3	%	26.4	%
Operating income margin in %	19.6	%	15.4	%					17.1	%	14.2	%
Delivered Operating income in € million	503		373		35.0	%	32.4	%	863		657		31.2	%	28.3	%
Care Coordination
Revenue in € million	349		278		25.5	%	23.0	%	686		586		17.0	%	14.1	%
Operating income in € million	42		1		n.a.		n.a.		89		41		119.2	%	114.0	%
Operating income margin in %	12.0	%	0.3	%					13.0	%	6.9	%
Delivered Operating income in € million	32		(1	)	n.a.		n.a.		71		33		116.5	%	111.3	%

Key metrics Dialysis Care Services

	Six months ended June 30
unaudited	Clinics	Growth in %		De novos	Patients	Growth in %		Treatments	Growth in %
Total	4,036	1	%	60	347,683	2	%	26,526,147	4	%
North America	2,614	1	%	33	212,149	2	%	16,303,730	4	%
EMEA	797	2	%	13	67,220	2	%	5,056,261	2	%
Asia-Pacific	380	-5	%	11	31,893	0	%	2,284,425	2	%
Latin America	245	6	%	3	36,421	8	%	2,881,731	11	%

Key metrics Care Coordination

	Six months ended June 30
unaudited	2020	2019	Change		Change at cc
North America
Member months under medical cost management(1)	345,675	336,256	2.8	%
Medical cost under management (in € million)(1)	2,259	2,174	3.9	%	1.4	%
Care Coordination patient encounters	384,017	550,233	-30.2	%

(1) Data presented for the ESCO metrics are subject to finalization by CMS, which may result in changes from previously reported metrics.

Key metrics

7

Quality data(1)

	North America		EMEA		Latin America		Asia-Pacific
in % of patients	Q2 2020	Q2 2019	Q2 2020	Q2 2019	Q2 2020	Q2 2019	Q2 2020	Q2 2019
Kt/V > 1.2	97	97	93	94	90	90	94	96
Hemoglobin = 10-12 g/dl	73	71	82	82	46	49	52	56
Calcium = 8.4-10.2 mg/dl	81	83	77	79	75	76	72	73
Albumin > 3.5 g/dl(1)	80	80	89	89	90	92	89	90
Phosphate < 5.5 mg/dl	57	60	77	79	77	76	65	64
Patients without catheter (after 90 days)	80	82	77	79	79	80	81	85
in days
Days in hospital per patient year	9.8	11.0	7.3	7.9	3.9	4.2	2.6	2.7

(1) Definitions cf. Annual Report 2019, Section “Non-Financial Group Report”

Quality data

8

Reconciliation of non-IFRS financial measures to the most directly comparable IFRS financial measures

	Three months ended June 30				Six months ended June 30
in € million, unaudited	2020		2019		2020		2019
Delivered Operating Income reconciliation
Total
Operating income	656		521		1,211		1,058
less noncontrolling interests	(76	)	(61	)	(144	)	(118	)
Delivered Operating Income	580		460		1,067		940
North America
Operating income	609		429		1,073		801
less noncontrolling interests	(74	)	(57	)	(139	)	(111	)
Delivered Operating Income	535		372		934		690
Dialysis
Operating income	567		428		984		760
less noncontrolling interests	(64	)	(55	)	(121	)	(103	)
Delivered Operating Income	503		373		863		657
Care Coordination
Operating income	42		1		89		41
less noncontrolling interests	(10	)	(2	)	(18	)	(8	)
Delivered Operating Income	32		(1	)	71		33
EMEA
Operating income	78		96		179		235
less noncontrolling interests	(1	)	(2	)	(2	)	(3	)
Delivered Operating Income	77		94		177		232
Asia-Pacific
Operating income	63		69		140		164
less noncontrolling interests	(1	)	(2	)	(3	)	(4	)
Delivered Operating Income	62		67		137		160
Dialysis
Operating income	70		64		144		154
less noncontrolling interests	(2	)	(1	)	(3	)	(4	)
Delivered Operating Income	68		63		141		150
Care Coordination
Operating income	(7	)	5		(4	)	10
less noncontrolling interests	1		(1	)	0		0
Delivered Operating Income	(6	)	4		(4	)	10
Latin America
Operating income	11		6		18		17
less noncontrolling interests	0		0		0		0
Delivered Operating Income	11		6		18		17
Corporate
Operating income	(105	)	(79	)	(199	)	(159	)
less noncontrolling interests	0		0		0		0
Delivered Operating Income	(105	)	(79	)	(199	)	(159	)

Reconciliation

9

Reconciliation of non-IFRS financial measures to the most directly comparable IFRS financial measures

											(Gain) loss related								Change
									Cost		to divestitures of			Results			Change		(adjusted
	Results			Results			NxStage		optimization		Care Coordination			2019			(adjusted		results)
in € million, except share data, unaudited	2020			2019			costs		costs		activities			adjusted			results)		at cc
Three months ended June 30
Total revenue	4,557			4,345										4,345			4.9	%	4.7	%
EBITDA	1,066			908			4		3		(11		)	904			18.0	%	16.6	%
Total operating income	656			521			4		3		(11		)	517			27.0	%	25.1	%
North America	609			429			4		3		(11		)	425			43.7	%	40.9	%
Dialysis	567			428			4		3					435			30.5	%	28.0	%
Care Coordination	42			1							(11		)	(10		)	n.a.		n.a.
EMEA	78			96										96			-19.5	%	-18.6	%
Asia-Pacific	63			69										69			-8.7	%	-9.5	%
Dialysis	70			64										64			8.0	%	6.5	%
Care Coordination	(7		)	5										5			n.a.		n.a.
Latin America	11			6										6			85.5	%	110.0	%
Corporate	(105		)	(79		)			0					(79		)	33.1	%	32.7	%
Interest expense, net	92			114										114			-19.6	%	-19.7	%
Income tax expense	137			92			1		1		(2		)	92			50.3	%	47.8	%
Net income attributable to noncontrolling interests	76			61										61			24.8	%	22.2	%
Net income(1)	351			254			3		2		(9		)	250			40.3	%	37.9	%
Basic earnings per share	€	1.20		€	0.84		€	0.01	€	0.00	€	(0.03	)	€	0.82		45.4	%	43.0	%
Six months ended June 30
Total revenue	9,045			8,478										8,478			6.7	%	5.8	%
EBITDA	2,022			1,807			20		7		(11		)	1,823			10.9	%	9.2	%
Total operating income	1,211			1,058			20		7		(11		)	1,074			12.8	%	10.8	%
North America	1,073			801			20		7		(11		)	817			31.4	%	28.4	%
Dialysis	984			760			20		7					787			25.0	%	22.2	%
Care Coordination	89			41							(11		)	30			204.7	%	197.4	%
EMEA	179			235										235			-23.7	%	-23.3	%
Asia-Pacific	140			164										164			-14.6	%	-15.3	%
Dialysis	144			154										154			-5.8	%	-7.0	%
Care Coordination	(4		)	10										10			n.a.		n.a.
Latin America	18			17										17			2.9	%	11.4	%
Corporate	(199		)	(159		)			0					(159		)	25.0	%	24.5	%
Interest expense, net	196			222										222			-11.7	%	-12.5	%
Income tax expense	237			193			5		2		(2		)	198			20.4	%	18.0	%
Net income attributable to noncontrolling interests	144			118										118			21.8	%	18.8	%
Net income(1)	634			525			15		5		(9		)	536			18.3	%	16.0	%
Basic earnings per share	€	2.15		€	1.72		€	0.05	€	0.02	€	(0.03	)	€	1.76		22.2	%	19.8	%

(1) Attributable to shareholders of FMC-AG & Co. KGaA

10

Outlook 2020

		Outlook 2020
	Results 2019	(at Constant Currency)
Revenue(1)	€17,477 M	mid to high single digit growth rate
Operating income(1)	€2,356 M	mid to high single digit growth rate
Delivered Operating Income(1)	€2,117 M	mid to high single digit growth rate
Net income(1),(2)	€1,236 M	mid to high single digit growth rate
Basic earnings per share growth(1),(2) at Constant Currency	—	assessed based on expected development of net income and shares outstanding
Capital expenditures	€1.1 BN	€1.1 - €1.3 BN
Acquisitions and investments(3)	€2.2 BN	€0.5 - €0.7 BN
Net cash provided by (used in) operating activities in % of revenue	14.7%	> 12.5%
Free cash flow in % of revenue	8.3%	> 5%
Net leverage ratio	3.2	< 3.5
ROIC	6.1%	> 6.0%
Dividend per share(4)	€1.20	assessed based on expected development of net income and shares outstanding
Employees(5)	124,736	> 124,000
Research and development expenses	€168 M	€210 - €230 M

(1)Outlook 2020 inclusive of anticipated COVID-19 effects and excluding special items. Special items are effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of giving guidance. Growth rates based on adjusted results 2019 including IFRS 16 implementation and NxStage operations.

(2)  Net income attributable to shareholders of FMC-AG & Co. KGaA.

(3)Excluding investments in debt securities.

(4)Results 2019: proposal to be approved by the 2020 Annual General Meeting.

(5)Full-time equivalents.

Outlook

11